Dopamine-targeting treatments show only modest benefits for anhedonia, prompting calls for new research approaches

Dopamine has long been considered central to understanding anhedonia—the loss of pleasure, interest and motivation that is a common feature of depression and other mental health conditions. However, a new international expert report published in BMJ Mental Health suggests that dopamine alone cannot explain the condition and that future research must look beyond a single biological pathway.

Read it at Medical Xpress ↗

← Front page